Slide 1: Financial Statements Webinar 2021
Financial Statements Webinar 2021 Welcome!
Slide 2: Today's agenda
Today’s agenda § Modulight in brief § Our strategy and targets § Key takeaways from 2021 § Project pipeline § Q&A 2
Slide 3: Modulight in brief
Modulight in brief Modulight provides lasers and optics for demanding applications EBITDA, % average 44 % 2018-2021 Medicine- ja Biomedicine Other high-value add applications Projects with • Oncology (cancer diseases) • Modulight provides laser • Quantum computing commercialization products solution
Slide 4: We do laser and optics for a better life
benefits We do laser and optics for a better life Photoimmunotherapy combines photodynamic therapy and immunotherapy Benefits of photoimmunotherapy ü Photosensitizer covalently conjugated to antibody that has affinity for tumor cells (“third-generation photosensitizer”) Non-invasive and non-burdenin
Slide 5: A significant customer base
A significant customer base, consisting of well-known pharmaceutical and technology companies Medicine and Biomedicine Other high-value add applications Modulight’s customer base on medical and biomedical industries Modulight’s customer base on other high-value include well-known hospitals, universi
Slide 6: Significant business opportunities
Significant business opportunities offered by the pharmaceutical market, supported by synergistic business opportunities related to industrial applications Oncology (cancer diseases) Ophthalmological Genetics and Diagnostics diseases Market size billion. $ 1 Market size billion $ 2 Market size billi
Slide 7: Significant potential in indications with high unmet need
Significant potential in indications with high unmet need McKinsey study shows high unmet need in several tumor types1) Pancreatic Pre-clinical HCC (liver) Pre-clinical Lu ng NSCLC-Other CE/FDA approved Esoph ageal CE/FDA approved Glioblastoma Clinical trial Head & neck CE approved Ovarian Pre-clini
Slide 8: Synergy opportunities for other applications
Synergy opportunities for other applications Communication Digital press Quantum Computing AR/VR-technology Environmental sensing 3D-sensing 8
Slide 9: Business objectives and dividend policy
Business objectives and dividend policy Long Term Objectives Dividend Policy Business Objective: Financial Objectives: Proceed to large-scale Maintain strong Maintain strong In the coming years, Modulight commercial deployment1 with revenue growth profitability will focus on financing the company’s
Slide 10: Growth Strategy
Growth Strategy Strategic Key Factors Increasing Geographical Expanding the Opportunities for Continuous production expansion product range expansion in the investments in capacity other indications field of cloud laser technology analytics Modulight plans to Modulight intends to Modulight's strateg
Slide 11: Revenue model
Revenue model The objective is revenue, based on the Customized R&D projects based on the Best Efforts principle, share of pharmaceutical or treatment without revenue risk for Modulight fees, or the utilization rate of industrial applications. Current pharmaceutical and biomedical projects are mostl
Slide 12: Record number of new projects, but headwinds
Record number of new projects, but headwinds q A record number of new projects v Modulight initiated a record-number of new projects with significant customers v Successful recruiting of new employees, especially for R&D v Investment program progressing according to plan, program was expanded v Seve
Slide 13: Key figures 2021
Key figures 2021 Key Figures1) (thousand euro, unless stated otherwise) 07-12/2021 07-12/2020 01-12/20212) 01-12/20202) Net Sales 4 511 6 390 9 071 10 062 EBITDA -2 690 3 862 461 5 787 EBITDA-% -59.6 % 60.4 % 5.1% 57.5 % Operating result -3 351 3 347 -753 4 712 Operating result % -74.3 % 52.4 % -8.3
Slide 14: A rapidly widening R&D portfolio in 2021
A rapidly widening R&D portfolio in 2021 25 Total number of project with commercialization potential In 2021 we initiated a record- 20 number (8) of new projects with significant customers 15 § A rapidly widening R&D portfolio mitigates the inherent risks with bioscience projects and 10 increases ou
Slide 15: Significant progress with several projects
Significant progress with several projects CASE EXAMPLE “We have successfully Treating age-related eye diseases continued our efforts § Modulight is developing a photodynamic laser to offer to provide therapy (PDT) solution in collaboration with a major pharmaceutical company listed on new treatment
Slide 16: Examples of new projects started in 2021
Examples of new projects started in 2021 Customer: US based start-up, listed on Customer: US based privately held Customer: US based privately held Nasdaq biotech company company Indication: Using clinical laser for treating Indication: Using clinical laser for Indication: Using clinical laser in bl
Slide 17: Strengths
Strengths 1 2 3 4 5 – – – – – Over 20 years of Scalability and A significant Significant Strong financial experience in better clientele business performance. medical and laser therapeutic consisting of opportunities technology performance well-known offered by the enabled by pharmaceutical pharmace
Slide 18: Thank you! Questions?
Thank you! Questions? LEARN MORE AND FOLLOW US IN TWITTER, FACEBOOK, YOUTUBE AND INSTAGRAM: 18